Influence of gender and HIV transmission group on initial highly active antiretroviral therapy prescription and treatment response

HIV Medicine

Volumn 7, Issue 8, 2006, Pages 520-529

  Fardet, L ^a,d   Mary Krause, Mary ^a   Heard, I ^b   Partisani, M ^c   Costagliola, D ^a  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d HÔPITAL SAINT ANTOINE   (France)

Author keywords

Clinical and biological response; First HAART prescription; Gender; HIV infection; HIV transmission group

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BLOOD TRANSFUSION; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG UTILIZATION; FEMALE; FRANCE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INTRAVENOUS DRUG ABUSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SEX DIFFERENCE; SURVIVAL RATE; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FRANCE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME;

EID: 33750994659     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2006.00414.x     Document Type: Article

References (38)

1. Montaner JS, Reiss P, Cooper D et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial. J Am Med Assoc 1998; 279: 930-937.
2. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
3. Egger M, Hirschel B, Francioli P et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. Br Med J 1997; 315: 1194-1199.
4. Cunningham WE, Markson LE, Andersen RM et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. J Acquir Immune Defic Syndr 2000; 25: 115-123.
5. Hsu LC, Vittinghoff E, Katz MH, Schwarcz SK. Predictors of use of highly antiretroviral therapy (HAART) among persons with AIDS in San Francisco, 1996-99. J Acquir Immune Defic Syndr 2001; 28: 345-350.
6. Junghans C, Low N, Chan P, Witschi A, Vernazza P, Egger M. Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study. AIDS 1999; 13: 2547-2554.
7. Poundstone KE, Chaisson RE, Moore RD. Differences in VIH disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS 2001; 15: 1115-1123.
8. Mocroft A, Madge S, Johnson AM et al. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART and survival. J Acquir Immune Defic Syndr 1999; 22: 369-378.
9. Mocroft A, Gill MJ, Davidson W, Phillips AN. Are the gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care? J Acquir Immune Defic Syndr 2000; 24: 475-482.
10. Pezzotti P, d'Arminio Monforte A, Bugarini R et al. Antiretroviral therapy in VIH-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values? Eur J Epidemiol 2000; 16: 919-926.
11. Mcnaghten AD, Hanson DL, Dworkin MS, Jones JL. Differences in prescription of antiretroviral therapy in a large cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32: 499-505.
12. Turner BJ, Markson LE, Mckee LJ, Houchens R, Fanning T. Health care delivery, zidovudine use, and survival of women and men with AIDS. J Acquir Immune Defic Syndr 1994; 7: 1250-1262.
13. Stein MD, Piette J, Mor V et al. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med 1991; 6: 35-40.
14. Crystal S, Sambamoorthi U, Merzel C. The diffusion of innovation in AIDS treatment: Zidovudine use in two New Jersey cohorts. Health Serv Res 1995; 30: 593-614.
15. Tassie JM, Gasnault J, Bentata M et al. Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 1999; 13: 1881-1887.
16. The Antiretroviral Therapy (ART) Cohort Collaboration. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: Analysis of propective studies. Lancet 2003; 362: 679-686.
17. Murri R, Lepri AC, Phillips AN et al. Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: Evidence from the I. Co.N.A. Study. J Acquir Immune Defic Syndr 2003; 34: 184-190.
18. Prise en Charge des Personnes Infectées par le VIH: Recommandations du Groupe d'Experts. Rapport 2002 sous la Direction du Pr Delfraissy. Paris, France: Ed. Flammarion, Coll. Médecine-Sciences, 2002.
19. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002; 51: 1-55.
20. Ghani AC, Donnelly CA, Anderson RM. Patterns of antiretroviral use in the United States of America: Analysis of three observational databases. HIV Med 2003; 4: 24-32.
21. Lanoy E, Mary-Krause M, Tattevin P et al. How does delayed access to care influence the survival of HIV patients during the HAART era? XV International AIDS Conference. Bangkok, Thailand, July 2004 [Abstract Thpeb7138].
22. Lanoy E, Mary-Krause M, Tattevin P et al. Predictors of losses to follow-up among HIV-seropositive patients: Critical role of recent HIV diagnosis. J Clin Epidemiol 2006; 59: 829-835.
23. Moore AL, Kirk O, Johnson AM et al. Virologic, immunologic and clinical response to highly active antiretroviral therapy: The gender issue revisited. J Acquir Immune Defic Syndr 2003; 32: 452-461.
24. Raboud JM, Rae S, Woods R, Harris M, Montaner JS; INCAS and AVANTI Study Groups. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 2002; 16: 1627-1632.
25. Le Moing V, Chene G, Carrieri MP et al. Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001; 27: 372-376.
26. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
27. Haubrich RH, Little SJ, Currier JS et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS 1999; 13: 1099-1107.
28. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 15: 1115-1121.
29. Ammassari A, Trotta MP, Murri R et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr 2002; 31: S123-S127.
30. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The Manif 2000 Study Group. AIDS 2000; 14: 151-155.
31. Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr 2001; 27: 251-259.
32. Escobar I, Campo M, Martin J, Fernandez-Shaw C, Pulido F, Rubio R. Factors affecting patient adherence to highly active antiretroviral therapy. Ann Pharmacother 2003; 37: 775-781.
33. Tucker JS, Burnam MA, Sherbourne CD, Kung FY, Gifford AL. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. Am J Med 2003; 114: 573-580.
34. Bouhnik AD, Chesney M, Carrieri P et al. Nonadherence among HIV-infected injecting drug users: The impact of social instability. J Acquir Immune Defic Syndr 2002; 31: S149-S153.
35. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP; APROCO Cohort Study Group. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: From a predictive to a dynamic approach. Soc Sci Med 2002; 54: 1481-1496.
36. D'Arminio Monforte A, Cozzi-Lepri A, Phillips A et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: Results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr 2005; 38: 407-416.
37. Wilkin TJ, Gulick RM. Antiretroviral therapy. When and what to start - an American perspective. Curr Infect Dis Rep 2003; 5: 339-348.
38. Phillips AN, Lepri AC, Lampe F, Johnson M, Sabin CA. When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies. AIDS 2003; 17: 1863-1869.